Human Sinusoidal Microvascular Endothelial Cells (HLSMEC)

Background: 

       Human Liver Sinusoidal Microvascular Endothelial Cells, These Anti Free Human Primary Cells Were Initiated From Normal Human Liver Tissue By Isolation Following Discharge Treatment Of Tissue Without The Use Of Positive Selection Of Antibodies.

Animal Species/Organism: Human 

Tissue And Cell Type: Liver Tissue

Morphology: Endothelial Cell Like, Adherent Growth 

Medium And Culture Conditions: Complete Growth Medium And Culture Boost ™ Classic Cell Culture Medium (product No.: 4Z0-500) 

Gas Phase: Air, 95%; Carbon Dioxide, 5%. Temperature: 37 ℃. 

Complete Cryopreservation Solution:Cell Freezing Medium (4Z0-705)

Human Sinus Microvascular Endothelial Cell (HLSMEC) Ex Warehouse Detection Index: 

Note: This product is for scientific research only

"Primary human liver co-culture with flow and Kupffer cell integration on microfluidic liver-on-a-chip"  Mazur (Dissertation thesis) 2015.

"High levels of oncomiR-21 contribute to the senescence-induced growth arrest in normal human cells and its knock-down increases the replicative lifespan" Delago et al. Aging Cell, 2013.

"Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density" Zhu and Chen, US Patent 7658916B2, 2010.

"Cannabinoid‐2 receptor agonist HU‐308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis" Rajesh et al. J Leukocyte Biology, 2007.

"Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury" Batkai et al. FASEB Journal, 2007.

"An adiponectin receptor, T-cadherin, was selectively expressed in intratumoral capillary endothelial cells in hepatocellular carcinoma: possible cross talk between T-cadherin and FGF-2 pathways" Adachi et al. Virchows Archiv, 2006.

"Dexamethasone-mediated up-regulation of the mannose receptor improves the delivery of recombinant glucocerebrosidase to Gaucher macrophages" Zhu et al. J Pharmacology and Experimental Therapeutics, 2003.

SDS

ACBRI 566